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Abstract  
Background: Located in the Pacific Ocean between Australia and New Zealand, the unique 
population isolate of Norfolk Island has been shown to exhibit increased prevalence of metabolic 
disorders (type-2 diabetes, cardiovascular disease) compared to mainland Australia. We 
investigated this well-established genetic isolate, utilising its unique genomic structure to increase 
the ability to detect related genetic markers. A pedigree-based genome-wide association study of 
16 routinely collected blood-based clinical traits in 382 Norfolk Island individuals was performed. 
Results: A striking association peak was located at chromosome 2q37.1 for both total bilirubin and 
direct bilirubin, with 29 SNPs reaching statistical significance (P<1.84x10-7). Strong linkage 
disequilibrium was observed across a 200 kb region spanning the UDP-glucuronosyltransferase 
family, including UGT1A1, an enzyme known to metabolise bilirubin. Given the epidemiological 
literature suggesting negative association between CVD-risk and serum bilirubin we further 
explored potential associations using stepwise multivariate regression, revealing significant 
association between direct bilirubin concentration and type-2 diabetes risk. In the Norfolk Island 
cohort increased direct bilirubin was associated with a 28% reduction in type-2 diabetes risk (OR: 
0.72, 95% CI: 0.57-0.91, P=0.005). When adjusted for genotypic effects the overall model was 
validated, with the adjusted model predicting a 30% reduction in type-2 diabetes risk with increasing 
direct bilirubin concentrations (OR: 0.70, 95% CI: 0.53-0.89, P=0.0001). Conclusions: In summary, a 
pedigree-based GWAS of blood-based clinical traits in the Norfolk Island population has identified 
variants within the UDPGT family directly associated with serum bilirubin levels, which is in turn 
implicated with reduced risk of developing type-2 diabetes within this population. 
 
Keywords: 
Norfolk Island; GWAS; Bilirubin; type-2 diabetes; UGT1A1  
3 
Background 
 
This study examined a large multi-generational pedigree from the isolated population of Norfolk 
Island to identify genomic variants (SNPs – single nucleotide polymorphisms) associated with 
routinely collected blood-based clinical traits. The Norfolk Island population is a genetic isolate with 
strong family groups and a well-documented family genealogy [1]. Norfolk Island is a small volcanic 
island located in the Pacific Ocean between Australia (about 1600 km north-east of Sydney) and 
New Zealand (1077 km north-west of Auckland). Alongside geographic isolation, a unique history 
has shaped the genomic architecture of the current pedigree members resulting in an admixed 
population with both European and Polynesian ancestry [2]. Recent estimation of the admixture in 
the Norfolk Island cohort reported 88% European ancestry and 12% Polynesian ancestry [2]. 
 
To date the Norfolk Island Health Study (NIHS) has collected data and samples for 1199 Norfolk 
Islanders, 52% (N=624) of whom were found to have direct links to the original founders. Using this 
in-depth genealogical information a large multi-generational Norfolk pedigree was reconstructed 
[1]. Several studies have established admixture scores and presence of founder effects within the 
Norfolk Island pedigree [1–3] and the pedigree has been shown to have sufficient power to detect 
genetic loci influencing complex traits via linkage and association [4–7].  
 
The Norfolk Island population has high rates of metabolic syndrome [7] and cardiovascular related 
risk factor traits, especially obesity, compared to mainland Australia. Research on the Norfolk 
pedigree has shown that traits for obesity, dyslipidaemia, blood glucose and hypertension exhibit a 
substantial genetic component, with heritability estimates ranging from 30% for systolic blood 
pressure (SBP) to 63% for low density lipoproteins (LDL) cholesterol [1, 4, 5]. In addition, factor 
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analysis identified “composite” phenotypes with high heritability [5], suggesting that common 
gene(s) underlie cardiovascular disease-related phenotypes. Furthermore, genetic linkage analysis 
in the Norfolk Island pedigree has successfully identified previously documented regions associated 
with cardiovascular disease risk traits, the most significant being for SBP on chromosome 1 (1p36) 
[4].  
 
Reported rates of type-2 diabetes within the Norfolk Island population are similar to mainland 
Australia (4-8%). However, a significantly higher proportion of individuals had fasting blood glucose 
in excess of normal ranges (>5 mmol/L), suggesting a high prevalence of pre-diabetes and possible 
under-diagnosis of type-2 diabetes [4, 8]. Additionally, clinical diagnosis of type-2 diabetes using 
AUSDRISK [9] identified that 42% of the Norfolk Island population were at high-risk of developing 
the disease [7].  
 
Bilirubin is a component of haemoglobin, formed during metabolic breakdown in the liver. Total 
serum bilirubin measures both water-soluble (direct-) and fat-soluble (indirect-) bilirubin. Bilirubin 
is also a potent antioxidant and as such has a vital role in the protection of the body against reactive 
oxygen species [10–12]. Numerous epidemiological analyses have reported strong negative 
associations between CVD-risk and serum bilirubin levels . Very few studies investigating the link 
between type-2 diabetes and serum bilirubin concentration have been conducted [13], although 
recently an association with mortality in a type-2 diabetic cohort was observed [14].   Serum bilirubin 
concentration has been shown to be tightly regulated by the UDP-glucuronosyltransferase (UDPGT) 
enzyme family, with several large GWAS and linkage studies identifying variants within UGT1A in 
particular [15–18]. This is suggestive of a potentially heritable metabolic disease factor, for which a 
recent study provides further supportive evidence; a Mendelian randomization study exploring total 
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bilirubin levels in a prospective study found further evidence for a protective role in type-2 diabetes 
[19]. 
 
The aim of this study was to update the previously calculated heritabilities for a range of blood-
based traits relating to CVD risk in the Norfolk Island cohort and to perform genome-wide 
association studies (GWASs) of the heritable traits using a pedigree-based approach.  
6 
Results 
 
Heritability of Individual Metabolic Traits 
A description of the blood-based clinical traits investigated in this study, including summary 
statistics, is shown in Additional File 1. The latest pedigree relationship information and GenABEL 
were used to calculate heritability (h2) statistics for all traits profiled in the Norfolk Island cohort. In 
total, 16 traits (out of 19) yielded statistically significant h2 values ranging from 0.225 – 0.563 
(nominal P<0.05). The average heritability was 0.39 and 8 traits exhibited a higher than average 
heritability (total protein, globin, total bilirubin, LDL-C, cholesterol, alkaline phosphatase, and urea) 
the most heritable trait being total protein (h2=0.563, P=2.26x10-4). A summary of all significantly 
heritable major blood-based clinical traits is shown in Table 1.  
 
GWAS of Metabolic Traits 
All 16 heritable blood-based clinical traits were screened for association separately; individual trait 
GWAS Manhattan plots can be viewed in Additional File 2. There were 2 traits with robustly 
associated clusters (i.e. SNPs in close proximity to each other); total bilirubin and direct bilirubin. It 
should be noted that a number of SNPs passed the adjusted significance threshold for liver function 
traits (i.e. GGT, AST, ADH). These traits exhibited numerous SNPs passing Meff adjustment, however 
robust 'peaks'/clusters of SNPs were not observed.  
 
Exploration of the Bilirubin Association on Chromosome 2q37.1 
The strongest observed association was seen between a cluster of 29 SNPs on chromosome 2q37.1 
passing a Meff adjusted threshold and total serum bilirubin (Fig 1 A, Table 2). The most robustly 
associated SNP was rs6744284 (P=1.87x10-16). A weaker association was observed for the same 
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cluster of SNPs on chromosome 2q37.1 with direct serum bilirubin levels (Fig 1 B). These 29 SNPs 
span a region of 189.8 kb, and lie directly on top of a complex locus that codes numerous isoforms 
of the UDP-glucuronosyltransferase (UGT) family (Fig 2).  
 
LD block identification 
Evidence of strong linkage disequilibrium (LD) across the 29 SNPs was observed in the Norfolk Island 
population (Fig 3); summarised LD statistics for the 29 SNPs: r2 (min = 0.026, 1st Quartile = 0.33, 
median = 0.49, mean = 0.51, 3rd Quartile = 0.72, max = 1.00), D' (min = 0.24, 1st Quartile = 0.82, 
median = 0.90, mean = 0.89,  3rd Quartile = 1.00, max = 1.00).. Haploview analysis identified 2 LD 
blocks across the region; the first block contained 9 SNPs and spanned 88 kb, the second block 
consisted of 19 SNPs and spanned a region of 74 kb. Further analysis of LD across 3 separate HapMap 
populations was conducted to compare with that obtained in the Norfolk Island cohort; CEU 
(European), CHD (Chinese) and JPT (Japanese). Due to the use of different SNP arrays, 25 of the 29 
SNPs were available across the 4 populations, thus the LD mapping was restricted to these 25 SNPs. 
The LD pattern for the Norfolk Island cohort was most similar to the CEU population, and extensively 
different from both of the Asian HapMap groups used (Additional File 3). LD appeared slightly 
stronger in the Norfolk Island SNPs than for CEU. Allele frequencies for the 25 SNPs in these 4 
populations are detailed in Additional File 4. 
 
Haplotype mapping and association with bilirubin levels 
Haploview association analysis was performed on the individual 29 SNP 'markers', minor allele 
frequencies (MAF) and association statistics are documented in Table 3 (for additional information 
see Additional File 5). All 29 SNPs exhibited significantly (P<1.0x10-4) increased MAF in the high 
serum bilirubin group. The most significantly associated marker was rs17863787; the frequency of 
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the ‘G’ allele was observed to be 62.3% in those with high serum bilirubin and 24.9% in those with 
normal serum bilirubin (P=5.51x10-17).  
 
To further investigate the association of genomic structure across the chr2q37.1 region with serum 
bilirubin, a haplotype association analysis was conducted in Haploview. There were a total of 6 
haplotypes inferred for LD block 1 and 7 haplotypes for LD block 2 (Additional file 6); haplotypes 
present in >1% of the total population are shown. The block 1 haplotype most significantly 
associated with the high bilirubin group was 'TAAGTGGGA', which is estimated to exist at 20.3% in 
the total population. This haplotype was observed in 40.3% of the high serum bilirubin group, and 
17.2% of the normal group (P=4.59x10-9). The most abundant block 1 haplotype ('CGGTCCACT', 
33.6% of total population) was observed to be significantly associated with the normal serum 
bilirubin group; 36.9% normal vs 19% high (P=9.31x10-5). The LD block 2 haplotype most significantly 
associated with high serum bilirubin was 'GGGCGTTGTGAGCTTGTTC'; which is estimated to be 
present in 18.8% of the total population. This haplotype was observed in 43.5% of the high serum 
bilirubin group, and 14.3% of the normal group (P=1.73x10-14). The most abundant block 2 haplotype 
('CAAATCCACTGTACGTCCT', 49.2% of total population) was observed to be significantly associated 
with the normal serum bilirubin group; 54.6% normal vs 26.1% high (P=3.51x10-9). Frequency and 
combination of the block specific haplotypes is illustrated in Fig 4. 
 
Nine tagging SNPs were identified that capture the allelic variance of the 29 SNPs (Table 4); the 
tagging analysis captured all 29 alleles at r2 >= 0.8 which contains 100 percent of alleles with mean 
r2 of 0.963. These SNPs could be used in future replication analyses to tag variation across the region 
in other populations. 
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Bilirubin Correlations with clinical metabolic syndrome and cardiovascular disease 
It is well established that serum bilirubin levels are inversely correlated with risk of developing 
cardiovascular disease [20–22]. Therefore this was investigated using the cardiovascular disease risk 
score previously calculated for the Norfolk Island population [7], along with potential relationships 
between other metabolic risk scores, including metabolic syndrome and type-2 diabetes (scores 
previously estimated [7]).  
 
A significant inverse relationship was observed between total serum bilirubin and the clinical risk 
score for metabolic syndrome. Of the 592 individuals with available data 66% had normal bilirubin 
levels and no metabolic syndrome, 11.5% had high bilirubin levels and no metabolic syndrome, 
25.3% had normal bilirubin and metabolic syndrome, 1.2% had high bilirubin and metabolic 
syndrome. A chi-squared contingency test followed by Fisher's exact showed that this was a 
significant observation; χ2=4.18 (P=0.04), Fisher's Exact OR=2.45 (P=0.03). This correlation suggests 
that Norfolk Island individuals with higher serum bilirubin levels are less likely to develop metabolic 
syndrome. 
 
Numerous studies have also attributed smoking behaviour to be associated with serum bilirubin 
levels [23–25]. This was tested in the Norfolk Island population using the students independent t-
test, and revealed a significant difference in mean serum bilirubin levels between smokers (6.46 
µmol/L) and non-smokers (8.12 µmol/L); t=3.99 with P=4.06x10-5.  
 
To further examine potential relationships a series of t-tests between a variety of quantitative 
metabolic syndrome/cardiovascular disease traits and categorised serum bilirubin group were 
performed. There were a total of 9 significant (P<0.05) trait correlations with categorised bilirubin 
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level, these were; body mass index (BMI), body fat, cholesterol/HDL-C ratio, total cholesterol, hip 
circumference, LDL-C, type-2 diabetes risk score, total protein and triglycerides (Table 5). These 
findings highlight traits that are consistent with previous literature [26, 27]. 
 
Body fat was observed to have the strongest correlation with serum bilirubin, with significantly 
reduced body fat composition in individuals who had high serum bilirubin levels. Unlike previous 
observations [20, 27, 28], cardiovascular disease risk score was not significantly reduced in those 
individuals with higher serum bilirubin, whereas, type-2 diabetes risk did show a significant 
reduction in the higher bilirubin group, consistent with previous literature [26, 29].  
 
Genotype effects on metabolic syndrome, type-2 diabetes and cardiovascular disease traits 
To further explore the above approach, associations between the 29 significantly associated SNPs 
and metabolic traits other than serum bilirubin were explored. Traits which showed a significant 
(P<0.05) correlation with total serum bilirubin (Table 5) were selected. Only one trait was observed 
which showed a significant association with any of the 29 markers, this was type-2 diabetes-risk 
when categorised: “low”; “intermediate”, and “high” [9]. Using a chi-squared test rs2741012 and 
rs2741027 were significantly associated with type-2 diabetes-risk (χ2=9.63, P=0.0069). Again this 
was followed with a Fisher's Exact test which confirmed significance (P=0.0081). The same 
observation with the minor allele and suggestive protection was observed. 
 
To further investigate the above associations logistic regression was used to identify a model that 
predicts outcome (type-2 diabetes) from trait (bilirubin) and factors in potential modifiers 
(genotype). Logistic regression modelling identified direct bilirubin as being significantly associated 
with categorised type-2 diabetes risk (r2: 0.05, p-value: 0.005), suggesting that in the Norfolk Island 
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cohort increased direct bilirubin was associated with a 28% reduction in type-2 diabetes risk 
(OR:0.72, 95% CI: 0.57-0.91). Based on a bi-directional stepwise regression model approach 2 of the 
9 tagging SNPs remained significant; rs2741027 and rs6725478. These SNPs effectively tag the two 
major 'protective'/high bilirubin haplotypes. When included, the adjusted model remained 
significant (r2: 0.13, p-value: 0.0001) and confirmed the initial association; direct bilirubin (OR:0.70, 
95% CI: 0.53-0.89, p-value: 0.005): rs2741027 (OR:0.25, 95% CI: 0.10-0.58, p-value: 0.002), 
rs6725478 (OR:0.27, 95% CI: 0.10-0.63, p-value: 0.004). This indicates that when controlling for 
bilirubin levels genotype affects risk of type-2 diabetes within the Norfolk Island population. 
Therefore, inclusion of SNP genotypes when assessing the relationship between direct bilirubin and 
type-2 diabetes risk increases the accuracy of the 'risk' estimate within the Norfolk Island cohort. 
 
Functional Annotation of UDP-glucuronosyltransferase SNPs 
Investigation of the 29 SNPs revealed several of potential functional interest (SNP annotation Table 
6). Three SNPs are within the coding region of UGT1A6 (Table 6); rs1105880 (synonymous), 
rs1105879 and rs2070959 (non-synonymous). Further investigation with SNPnexus 
(http://www.snp-nexus.org/) revealed rs1105879 had a PolyPhen score of 'possibly damaging', 
indicating the usually conserved nature of the coded amino acid. Six SNPs were observed to reside 
within 5' prime untranslated regions (5'UTR); UGT1A1 (rs887829, rs3755319), UGT1A3 (rs2008589), 
UGT1A6 (rs7608175), UGT1A7 (rs7586110), and UGT1A9 (rs2741045).  
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Discussion 
 
We have identified a significant genomic association at 2q37.1 in the region of the UDP-
glucuronosyltransferase (UDPGT) enzyme family members, with direct and total serum bilirubin 
levels. Correlation analyses between metabolic syndrome related traits and serum bilirubin levels 
identified significant inverse relationships for numerous traits. Haplotype association testing 
revealed the presence of potentially protective haplotypes within the Norfolk Island population. 
Thus this study has identified a complex region which shows interplay between genomic and 
environmental conditions and has a large effect on overall serum bilirubin levels. 
 
Previous literature has suggested a linkage between bilirubin and metabolic risk with clinical 
associations observed between cardiovascular disease risk, obesity and bilirubin concentrations 
[20–22, 27] and more recently metabolic syndrome [30–34]. Therefore, we investigated potential 
relationships between bilirubin and metabolic traits in the Norfolk Island cohort. An inverse 
correlation between serum bilirubin and several important metabolic traits was observed, with the 
most notable being metabolic syndrome and type-2 diabetes risk. Given that metabolic syndrome 
and type-2 diabetes increase cardiovascular disease risk it is consistent with the current body of 
literature which documents inverse association between high serum bilirubin and cardiovascular 
disease risk (review [26]).  
 
Our analysis refined an association with serum bilirubin concentration to a 189.8 kb region on 
chromosome 2q37.1 with genotypic analyses revealing that the level of serum bilirubin was greatly 
increased in individuals with the rare allele. This region encodes one of the major drug metabolising 
families (UDP-glucuronosyltransferase, UDPGT) [35–37]; there are 9 documented UDPGT isoforms; 
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UGT1A1, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9 and UGT1A10 (Fig 2). 
UGT1A1 is well known to preferentially metabolise bilirubin and has been previously mapped in 
linkage and GWAS studies  [16–18, 38–43]. UGT1A3 and UGT1A4 also have been shown to have 
potential action with bilirubin [37]. However all family members, including UGT1A1, exhibit activity 
for numerous substrates and it is therefore possible that the gene effects are not mediated (entirely) 
by total bilirubin. Such pleotropic effects at this loci are likely to be the case as evidenced by the fact 
that adjustment for serum bilirubin in our modelling did not completely nullify the association 
between genotype and outcome. Future work is required to explore the effects and associations of 
other substrates with this genomic region.   
 
Mutations in UGT1A1 have also been associated with Crigler-Najjar syndromes types I and II and in 
Gilbert syndrome [44–46]. Gilbert Syndrome (GS) is a well-documented benign increase in serum 
bilirubin, and is caused by the reduced activity of UDPGT [47–51]. In line with the observations that 
serum bilirubin is inversely correlated with metabolic risk diabetic patients with GS are less likely to 
develop vascular dysfunctions [52]. Furthermore, the incidence of diabetes and cardiovascular 
disease risk mortality is lower in GS individuals, with one study exploring the efficacy of increasing 
serum bilirubin in type-2 diabetic patients [53].  Further evidence confirming the protective role of 
circulating bilirubin for type-2 diabetes has been reported in a prospective study [19]. 
 
Significant difference has been identified between functional polymorphisms within the UGT1A  
family between Caucasian and other populations [54]. Polymorphisms in the promoter region for 
UGT1A1 (2 bp TA insertion in the TATA box) increased activity in Caucasian GS patients; this was not 
observed in Asian and African GS patients or Pacific populations [54]. The authors suggest that due 
to the complex nature of environmental and genetic factors, unstable polymorphisms within 
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UGT1A1 may act to “fine-tune” plasma bilirubin levels on a population by population basis, meaning 
that the promoter variation explains the presence of GS in some populations, but in other 
populations it's more likely a combination of variants in the encoding region along with 
environmental factors [54], our data supports this hypothesis. Additionally, meta-analysis has 
demonstrated strong replication for a genetic influence on serum bilirubin levels of the UGT1A1 
locus (P<5x10-324), specifically at the proximal promoter region of UGT1A1 tagged by rs6742078 [40]. 
While we didn’t have genotype information for this SNP we were able to impute against the 1000 
Genomes panel to extrapolate associations between the two studies. Using imputed information 
we were able to illustrate that there is tight LD between rs6742078 and the top associated SNP from 
our study, rs6744284 (r2=0.85), suggesting that the Norfolk Island cohort exhibit a similar genetic 
pattern of association.  
 
We identified strong LD across the region of 2q37.1, potentially suggesting that the Norfolk Island 
population’s unique genomic structure is influencing serum bilirubin concentration. LD across the 
same region in data available through the HapMap project [55] showed that the Norfolk Island 
cohort exhibited an LD pattern similar to that observed in the European population (CEU), while 
both the Asian populations (Chinese and Japanese) exhibited very different genetic structure across 
this region. This is not unexpected because of the large amount of recent European admixture in 
the Norfolk population. Additionally, it was noted that haplotypes containing the minor allele(s) in 
the Norfolk Island population potentially conferred protection to metabolic disorders as measured 
by clinical metabolic syndrome and type-2 diabetes-risk. It is possible that selection is driving the 
presence of high serum bilirubin within populations, although this may be achieved by different 
variation across the region. It appears that in Europeans this variation is often in the promoter 
region, whereas in Asian and African populations this is not the case, and it is polymorphisms in the 
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gene body that seems to account for the associations with increased bilirubin. This strongly suggests 
that it is beneficial for a population to have a certain frequency of individuals with naturally high 
serum bilirubin, and potentially points to a complex interaction between environmental and 
genomic factors maintaining this. 
 
One significant association between 2 SNPs (rs2741012 and rs2741027) and categorised type-2 
diabetes-risk was observed. These two SNPs are just upstream of the promoter and 5'UTR region of 
the UDPGT family. It is likely that these SNPs are in LD with untyped polymorphisms (SNPs not on 
the 610quad chip) that reside in these regions and potentially form a LD block/haplotype in the 
Norfolk Island population which confers protection to type-2 diabetes as well as metabolic 
syndrome. Interestingly, and in support of our approach, this reduction in risk correlates well with 
previous work conducted in a large US cohort [13]; these variants (or variants tagged by them) may 
be functional, i.e. they might directly affect transcription and/or translation of the isoforms encoded 
by the UDPGT family. It is also possible that there are additional rare variants within the region that 
further influence serum bilirubin as recently evidenced by an exome sequencing study performed 
in elderly individuals [56].  
 
Given that bilirubin is a cheap and commonly measured laboratory test, routine screening of serum 
bilirubin levels could be beneficial in the stratification and treatment of metabolic disorders such as 
cardiovascular disease and type-2 diabetes. Identification of genes/variants that exhibit pleiotropic 
effects (effects of the same variant on multiple characteristics or disease risks) is an ultimate goal. 
The significant interaction observed here provides evidence that bilirubin may be affected by 
genetic and environmental factors and their interactions. 
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Conclusions 
 
In summary, this study identified strong associations of variants within the UGT1A family with 
regulation of serum bilirubin levels in the Norfolk Island population, which replicated previous 
GWAS and epidemiological findings. This successful implementation of pedigree-based analysis 
using the unique properties of the Norfolk Island cohort highlights a functional region that offers 
protective benefit from metabolic disease and further eludes to a potentially heritable component 
with the Norfolk Island population. Specific haplotype structure was significantly associated with 
increased serum bilirubin, and as such this study has identified a potential set of 'protective' 
haplotypes that exist within the Norfolk Island population. Further studies are warranted to validate 
these findings, with the next step being to explore these associations in larger outbred populations. 
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Methods 
 
Sample/cohort collection, Pedigree Information and Ethics 
The Norfolk Island Health Study (NIHS) is well established with regards to data collection and initial 
disease prevalence studies [4, 5, 8]. The Norfolk Island pedigree structure has been previously 
outlined [57], and subsequently updated [1]. The most recent update led to the reconstruction of a 
core-pedigree consisting of 1388 members coalescing over 11 generations (or 200 years) back to 
the original founders. [3, 7]. This study focuses on a reduced core-pedigree, meaning that 
individuals; a) are genetically related to the original founders, and b) have phenotype and genotype 
information available. The total number of individuals fitting these criteria was 382. All individuals 
gave written informed consent. Ethical approval was granted prior to the commencement of the 
study by the Griffith University Human Research Ethics Committee (ethical approval no: 
1300000485) and the project was carried out in accordance with the relevant guidelines, which 
complied with the Helsinki Declaration for human research. 
 
Heritability Analysis 
All 19 metabolic traits assessed in this analysis are part of the NIHS2000 collection [8]. Traits 
measured were: fasting plasma glucose, HDL-C, LDL-C, total plasma cholesterol, cholesterol-HDL-C 
ratio, triglycerides, creatinine, total protein, globin, albumin, urea, uric acid, total serum bilirubin, 
direct serum bilirubin, and numerous enzymes that are markers for liver/kidney function (ALT, AST, 
Alkaline Phosphatase, GGT, Lactate Dehydrogenase [LDH]). 
 
Heritability Estimates 
The R package and genetic analysis program GenABEL [58] was used to calculate heritability 
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estimates for all metabolic syndrome/cardiovascular disease related traits. The genetic kinship 
matrix derived from the SNP data and reconstructed core-pedigree was used to estimate trait 
heritability (h2 [narrow-sense heritability]) by polygenic modelling. All traits were screened for 
covariant effects of age and sex interactions  
 
Genome-wide SNP Genotyping 
EDTA anticoagulated venous blood samples were collected from all participants. Genomic DNA was 
extracted from blood buffy coats using standard phenol-chloroform procedures. DNA samples were 
genotyped according to the manufacturer’s instructions on Illumina Infinium High Density (HD) 
Human610-Quad DNA analysis BeadChip version 1. BeadChips were a four-sample format requiring 
200 ng of DNA per sample. Samples were scanned on the Illumina BeadArray 500GX Reader. Raw 
data was obtained using Illumina BeadScan image data acquisition software (version 2.3.0.13). Raw 
data from Illumina idat files were SNP genotyped in R using the CRLMM package [59]. Genotype 
data then underwent initial quality control routines using PLINK [60]. SNPs were filtered based on: 
minor allele frequency >0.01; call rate >0.95, and Hardy-Weinberg equilibrium testing p-value >10−5. 
After this initial quality control, 590,603 SNPs were exported from PLINK and imported into the 
CRAN package GenABEL [58]. Further filtering (including Mendelian inheritance violations and sex-
checking based on available X and Y markers) in GenABEL lead to the reduction of the SNP set to a 
total of ~480,000; this included removal of both X and Y chromosome SNPs after gender checking, 
as well as the removal of mitochondrial and XY SNPs.  
 
Genome-Wide Association Analysis 
A pedigree based GWAS analysis of all heritable traits was batched using custom R scripts and the 
package GenABEL [58]. GenABEL uses an additive approach and the loci are coded as 0, 1, 2 
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(corresponding to genotypes AA, AB, and BB, respectively). A detailed explanation of the association 
model and specific GWAS overview as implemented in the Norfolk Island was previously described 
[7]. Breifly, a correction was made for the relatedness inherent in the Norfolk Island population 
using the polygenic model with age and sex interactions, as well as genetic structure [the top 2 
genomic principal components of the complete SNP set as calculated by KING [61]]. The top two 
components were chosen as covariates because we found that these explained the majority of the 
variance in the outcomes being tested and because inclusion of additional, less informative 
components only served to reduce the parsimony of the models. For association analysis the 
mmscore function implemented in GenABEL was used. This function represents a mixed model 
approximation analysis for association between a trait and genetic polymorphism(s), and is 
specifically designed for association testing in samples of related individuals. This allows for per SNP 
association testing using a mixed model polygenic approach. After correcting for multiple testing, 
the study-wide significance was set based on Meff adjustment (P = 1.84x10−7). It should be noted 
that this Meff threshold is tailored to trait-wise associations, not multi-trait analyses therefore p-
values are adjusted on a per trait basis. Association statistics for every SNP for each trait were 
generated and output to compressed files (.gz.tar) for storage and future reference. GWAS 
Manhattan plots where generated for each trait association using a custom modified version of the 
GenABEL plot.scan.gwaa function (for all Manhattan plots see Additional File 2). Annotation of the 
robustly associated bilirubin SNPs identified as being functional was performed using: 
 http://brainarray.mbni.med.umich.edu/Brainarray/Database/SearchSNP/snpfunc.aspx.  
 
LD testing and Haplotype Association 
Genotype data for the chrq37.12 region was phased using SHAPEIT2 [62], which has functionality to 
deal with complex pedigree structures – implemented through the duoHMM algorithm. From this 
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process we observed no Mendelian errors before moving the phased data over to Haploview 
analyses. Haplotype/LD testing, SNP tagging and association analyses were all conducted in 
Haploview 4.2 [63]. LD blocks were determined using the default Haploview settings which infer LD 
based on a pairwise comparison of correlation (r2) values between SNPs. Haplotypes were inferred 
from the genotypes of SNPs which made up the identified LD blocks, and were only recorded if they 
existed in more than 1% of the population. Tagging SNPs were determined using the 'tagger' option 
of Haploview, using a pair-wise tagging method with a minimum observed r2 between pairs of 0.8. 
Association analyses were carried out on both markers (SNPs) and haplotypes using the inbuilt 
Haploview association function. A phenotype column was added to the dataset to allow a 
'case'/'control' experimental set-up; where case represented the high bilirubin group and control 
the normal bilirubin group. There were a total of 65 cases and 317 controls with 124 genotyped 
individuals missing phenotype information. Permutation testing was run to confirm the above 
association analyses for both marker and haplotype associations. To ensure the robustness of final 
P values the number of permutations was set at 1,000,000 (this should lead to a reduction of the 
FDR). A further exploration of potentially similar structure across the region spanned by the 29 SNPs 
was tested in 3 HapMap populations; CEU (European), CHD (Chinese), and JPT (Japanese). Due to 
data being generated on different genotype platforms (SNP chips), a final list of 25 consensus SNPs 
was retained for Haploview analysis for Norfolk Island and the 3 HapMap sets. Linkage 
disequilibrium plots across the 25 SNP region was generated for each of the 4 populations 
(Additional File 3).  
 
Correlations with metabolic traits 
Initial exploratory correlations between risk scores for cardiovascular disease and type-2 diabetes, 
clinically defined Metabolic Syndrome (categorical: 0 (no MetS), 1 (MetS)), and various related traits 
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were conducted in R 2.15.2 [64]. For all analyses total serum bilirubin levels were categorised into 
'normal' and 'high' groupings, with 'high' being defined as >14 µmol/L, this approximates a clinical 
cut-off and allows facilitates interpretation in line with existing clinical guidlines. For all other traits 
tested a standard student's t-test (as implemented in R) was used to test for a significant difference 
of means between the given trait and bilirubin level. There were two categorical traits tested for 
correlation with serum bilirubin levels; smoking and presence of metabolic syndrome. Smoking has 
been previously well documented to be associated with serum bilirubin levels [23], and was 
categorised in the Norfolk Island cohort as either 'yes' (smokers N=133) or 'no' (non-smokers 
N=458). Correlation testing between smoking and bilirubin was carried out using a 2x2 chi-squared 
contingency test, followed by a Fisher's Exact test. For correlation analysis between total serum 
bilirubin and metabolic syndrome there were a total of 598 individuals with available matched 
phenotype data; 'metabolic syndrome' (N=156) and 'no metabolic syndrome' (N=442). The clinical 
diagnosis of metabolic syndrome previously calculated for the Norfolk Island cohort was used [7]. A 
2x2 chi-squared contingency test was used to evaluate the significance, followed by a Fisher's Exact 
test as one of the tables cells contained a value less than 5%. Due to the initial exploratory nature 
of these analyses all tests are unadjusted, so nominal p-values are reported. Additionally, 
relatedness within the population is accounted for in later formal modelling using GLM regression. 
 
Regression Modelling testing association between outcome, trait and genotype 
To further explore associations between bilirubin, type-2 diabetes and the genotypic architecture 
across the UGT1A1 region regression modelling was conducted in R. To establish an initial 
association, separate logistic regression was conducted between categorised type-2 diabetes risk 
and total bilirubin and then direct bilirubin. Additionally a bi-directional stepwise logistic regression 
model was used to test the significance of each of the 9 tagging SNPs identified in the LD block 
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analysis. The model was not corrected for common covariates (age, sex, smoking, BMI) as these are 
all accounted for in the calculation of the AUSDRISK type-2 diabetes risk score (as previously 
calculated in the Norfolk Island cohort [7]). To address the issue of relatedness we included the 
average pedigree kinship as a covariate in the stepwise regression model. This was excluded from 
the final model indicating that in this instance relatedness is not a significant issue. Reported r2 
values use the Nagelkerke Index pseudo r2 as calculated in R. Model p values were generated from 
an ANOVA using the F distribution, which tests the null hypothesis that the coefficients represented 
in the overall regression model (represented by R 2 ) are equal to 0.  
23 
Web Resources 
Online Mendelian Inheritance in Man (http://www.omim.org) 
Catalogue of genome-wide association studies (http://www.genome.gov/gwastudies) 
BrainArray 
(http://brainarray.mbni.med.umich.edu/Brainarray/Database/SearchSNP/snpfunc.aspx) 
 
Competing interests 
The authors declare that they have no competing interests. 
 
Authors' contributions 
CB, MC, and JC carried out the genotype assays. MH curated phenotype and pedigree data. MB, RL, 
and DE participated in the design of the study and performed the statistical analysis. JB provided 
detailed statistical expertise and critical evaluation of methodology. MB, RL and LG conceived of the 
study, and participated in its design. DM and GC helped to draft the manuscript. All authors read 
and approved the final manuscript.  
 
Acknowledgements 
This research was supported by funding from a National Health and Medical Research Council of 
Australia (NHMRC) Project Grant. It was also supported by infrastructure purchased with Australian 
Government EIF Super Science Funds as part of the Therapeutic Innovation Australia – Queensland 
Node project. Also Miles Benton was supported by a Corbett Postgraduate Research Scholarship. 
We would like to acknowledge Amanda Miotto and also QUT for providing computational support 
for this project. Lastly, we extend our appreciation to the Norfolk Islanders who volunteered for this 
study.  
24 
List of abbreviations 
 
BMI  body mass index 
CEU  European Hapmap population 
CHD  Chinese Hapmap population 
CVD  cardiovascular disease 
DBP  diastolic blood pressure 
GS  Gilbert’s Syndrome 
GWAS  genome-wide association study 
h2  heritability (narrow-sense) 
HDL-C  high-density lipoprotein cholesterol 
JPT  Japanese Hapmap population 
LD  linkage disequilibrium 
LDL-C  low-density lipoprotein cholesterol 
MAF  minor allele frequency 
NI  Norfolk Island 
NIHS  Norfolk Island Health Study 
SBP  systolic blood pressure 
SNP  single nucleotide polymorphism  
25 
References 
 
1. Macgregor S, Bellis C, Lea RA, Cox H, Dyer T, Blangero J, Visscher PM, Griffiths LR: Legacy of 
mutiny on the Bounty: founder effect and admixture on Norfolk Island. Eur J Hum Genet 2010, 
18:67–72. 
2. McEvoy BP, Zhao ZZ, Macgregor S, Bellis C, Lea RA, Cox H, Montgomery GW, Griffiths LR, 
Visscher PM: European and Polynesian admixture in the Norfolk Island population. Heredity 
(Edinb) 2010:229–234. 
3. Benton MC, Stuart S, Bellis C, Macartney-Coxson D, Eccles D, Curran JE, Chambers G, Blangero J, 
Lea RA, Griffiths LR: “Mutiny on the Bounty”: the genetic history of Norfolk Island reveals 
extreme gender-biased admixture. Investig Genet 2015, 6:11. 
4. Bellis C, Cox HC, Dyer TD, Charlesworth JC, Begley KN, Quinlan S, Lea RA, Heath SC, Blangero J, 
Griffiths LR: Linkage mapping of CVD risk traits in the isolated Norfolk Island population. Hum 
Genet 2008, 124:543–552. 
5. Cox HC, Bellis C, Lea RA, Quinlan S, Hughes R, Dyer T, Charlesworth J, Blangero J, Griffiths LR: 
Principal Component and Linkage Analysis of Cardiovascular Risk Traits in the Norfolk Isolate. 
Hum Hered 2009, 68:55–64. 
6. Maher BH, Lea RA, Benton M, Cox HC, Bellis C, Carless M, Dyer TD, Curran J, Charlesworth JC, 
Buring JE, Kurth T, Chasman DI, Ridker PM, Schürks M, Blangero J, Griffiths LR: An X chromosome 
association scan of the Norfolk Island genetic isolate provides evidence for a novel migraine 
susceptibility locus at Xq12. PLoS One 2012, 7:e37903. 
7. Benton MC, Lea RA, Macartney-Coxson D, Carless MA, Göring HH, Bellis C, Hanna M, Eccles D, 
Chambers GK, Curran JE, Harper JL, Blangero J, Griffiths LR: Mapping eQTLs in the Norfolk Island 
Genetic Isolate Identifies Candidate Genes for CVD Risk Traits. Am J Hum Genet 2013, 93:1087–
99. 
8. Bellis C, Hughes RM, Begley KN, Quinlan S, Lea RA, Heath SC, Blangero J, Griffiths LR: 
Phenotypical characterisation of the isolated Norfolk Island population focusing on 
epidemiological indicators of cardiovascular disease. Hum Hered 2006, 60:211–219. 
9. Chen L, Magliano DJ, Balkau B, Colagiuri S, Zimmet PZ, Tonkin AM, Mitchell P, Phillips PJ, Shaw 
JE: Ausdrisk: An Australian Type 2 Diabetes Risk Assessment Tool Based on Demographic, 
Lifestyle and Simple Anthropometric Measures. Med J Aust 2010, 192:197–202. 
10. Stocker R, Yamamoto Y, McDonagh A, Glazer A, Ames B: Bilirubin is an antioxidant of possible 
physiological importance. Science (80- ) 1987, 235:1043–1046. 
11. Yamaguchi T, Terakado M, Horio F, Aoki K, Tanaka M, Nakajima H: Role of bilirubin as an 
antioxidant in an ischemia-reperfusion of rat liver and induction of heme oxygenase. Biochem 
26 
Biophys Res Commun 1996, 223:129–35. 
12. Baranano DE, Rao M, Ferris CD, Snyder SH: Biliverdin reductase: a major physiologic 
cytoprotectant. Proc Natl Acad Sci U S A 2002, 99:16093–8. 
13. Cheriyath P, Gorrepati VS, Peters I, Nookala V, Murphy ME, Srouji N, Fischman D: High Total 
Bilirubin as a Protective Factor for Diabetes Mellitus: An Analysis of NHANES Data From 1999 - 
2006. J Clin Med Res 2010, 2:201–6. 
14. Cox AJ, Ng MC-Y, Xu J, Langefeld CD, Koch KL, Dawson PA, Carr JJ, Freedman BI, Hsu F-C, 
Bowden DW: Association of SNPs in the UGT1A gene cluster with total bilirubin and mortality in 
the Diabetes Heart Study. Atherosclerosis 2013, 229:155–60. 
15. Grant DJ, Bell DA: Bilirubin UDP-glucuronosyltransferase 1A1 gene polymorphisms: 
susceptibility to oxidative damage and cancer? Mol Carcinog 2000, 29:198–204. 
16. Melton PE, Haack K, Göring HH, Laston S, Umans JG, Lee ET, Fabsitz RR, Devereux RB, Best LG, 
Maccluer JW, Almasy L, Cole SA: Genetic influences on serum bilirubin in American Indians: The 
Strong Heart Family Study. Am J Hum Biol 2011, 23:118–25. 
17. Chen G, Ramos E, Adeyemo A, Shriner D, Zhou J, Doumatey AP, Huang H, Erdos MR, Gerry NP, 
Herbert A, Bentley AR, Xu H, Charles BA, Christman MF, Rotimi CN: UGT1A1 is a major locus 
influencing bilirubin levels in African Americans. Eur J Hum Genet 2012, 20:463–8. 
18. Jylhävä J, Lyytikäinen L-P, Kähönen M, Hutri-Kähönen N, Kettunen J, Viikari J, Raitakari OT, 
Lehtimäki T, Hurme M: A genome-wide association study identifies UGT1A1 as a regulator of 
serum cell-free DNA in young adults: The Cardiovascular Risk in Young Finns Study. PLoS One 
2012, 7:e35426. 
19. Abbasi A, Deetman PE, Corpeleijn E, Gansevoort RT, Gans ROB, Hillege HL, van der Harst P, 
Stolk RP, Navis G, Alizadeh BZ, Bakker SJL: Bilirubin as a potential causal factor in type 2 diabetes 
risk: a Mendelian randomization study. Diabetes 2015, 64:1459–69. 
20. Schwertner H, Jackson W, Tolan G: Association of low serum concentration of bilirubin with 
increased risk of coronary artery disease. Clin Chem 1994, 40:18–23. 
21. Madhavan M, Wattigney WA, Srinivasan SR, Berenson GS: Serum bilirubin distribution and its 
relation to cardiovascular risk in children and young adults. Atherosclerosis 1997, 131:107–13. 
22. Novotný L, Vítek L: Inverse relationship between serum bilirubin and atherosclerosis in men: 
a meta-analysis of published studies. Exp Biol Med (Maywood) 2003, 228:568–71. 
23. Schwertner HA: Association of smoking and low serum bilirubin antioxidant 
concentrations1The views expressed in this article are those of the author and do not reflect the 
official policy of the Department of Defense or other Departments of the US Government.1. 
Atherosclerosis 1998, 136:383–387. 
27 
24. Hoydonck PG V.: Serum bilirubin concentration in a Belgian population: the association with 
smoking status and type of cigarettes. Int J Epidemiol 2001, 30:1465–1472. 
25. Jo J, Kimm H, Yun JE, Lee KJ, Jee SH: Cigarette smoking and serum bilirubin subtypes in 
healthy Korean men: the Korea Medical Institute study. J Prev Med Public Health 2012, 45:105–
12. 
26. Vítek L: The role of bilirubin in diabetes, metabolic syndrome, and cardiovascular diseases. 
Front Pharmacol 2012, 3:55. 
27. McArdle PF, Whitcomb BW, Tanner K, Mitchell BD, Shuldiner AR, Parsa A: Association between 
bilirubin and cardiovascular disease risk factors: using Mendelian randomization to assess causal 
inference. BMC Cardiovasc Disord 2012, 12:16. 
28. Lin J-P, Schwaiger JP, Cupples LA, O’Donnell CJ, Zheng G, Schoenborn V, Hunt SC, Joo J, 
Kronenberg F: Conditional linkage and genome-wide association studies identify UGT1A1 as a 
major gene for anti-atherogenic serum bilirubin levels--the Framingham Heart Study. 
Atherosclerosis 2009, 206:228–33. 
29. Wu Y, Li M, Xu M, Bi Y, Li X, Chen Y, Ning G, Wang W: Low serum total bilirubin concentrations 
are associated with increased prevalence of metabolic syndrome in Chinese. J Diabetes 2011, 
3:217–24. 
30. Andersson C, Weeke P, Fosbøl EL, Brendorp B, Køber L, Coutinho W, Sharma AM, Van Gaal L, 
Finer N, James WPT, Caterson ID, Rode RA, Torp-Pedersen C: Acute effect of weight loss on levels 
of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period 
of the Sibutramine Cardiovascular Outcome trial. Metabolism 2009, 58:1109–15. 
31. Guzek M, Jakubowski Z, Bandosz P, Wyrzykowski B, Smoczyński M, Jabloiska A, Zdrojewski T: 
Inverse association of serum bilirubin with metabolic syndrome and insulin resistance in Polish 
population. Przegla̧d Epidemiol 2012, 66:495–501. 
32. Choi SH, Yun KE, Choi HJ: Relationships between serum total bilirubin levels and metabolic 
syndrome in Korean adults. Nutr Metab Cardiovasc Dis 2013, 23:31–7. 
33. Kwon K-M, Kam J-H, Kim M-Y, Kim M-Y, Chung CH, Kim J-K, Linton JA, Eom A, Koh S-B, Kang H-
T: Inverse association between total bilirubin and metabolic syndrome in rural korean women. J 
Womens Health (Larchmt) 2011, 20:963–9. 
34. Jo J, Yun JE, Lee H, Kimm H, Jee SH: Total, direct, and indirect serum bilirubin concentrations 
and metabolic syndrome among the Korean population. Endocrine 2011, 39:182–9. 
35. Tephly TR, Burchell B: UDP-glucuronosyltransferases: a family of detoxifying enzymes. Trends 
Pharmacol Sci 1990, 11:276–279. 
36. Burchell B, Brierley CH, Rance D: Specificity of human UDP-Glucuronosyltransferases and 
xenobiotic glucuronidation. Life Sci 1995, 57:1819–1831. 
28 
37. Fisher MB, Paine MF, Strelevitz TJ, Wrighton SA: The role of hepatic and extrahepatic UDP-
glucuronosyltransferases in human drug metabolism. 2002. 
38. Lin J-P, Cupples LA, Wilson PWF, Heard-Costa N, O’Donnell CJ: Evidence for a gene influencing 
serum bilirubin on chromosome 2q telomere: a genomewide scan in the Framingham study. Am 
J Hum Genet 2003, 72:1029–34. 
39. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, Najjar SS, Zhao JH, Heath 
SC, Eyheramendy S, Papadakis K, Voight BF, Scott LJ, Zhang F, Farrall M, Tanaka T, Wallace C, 
Chambers JC, Khaw K-T, Nilsson P, van der Harst P, Polidoro S, Grobbee DE, Onland-Moret NC, 
Bots ML, Wain L V, Elliott KS, Teumer A, Luan J, Lucas G, et al.: Genome-wide association study 
identifies eight loci associated with blood pressure. Nat Genet 2009, 41:666–76. 
40. Johnson AD, Kavousi M, Smith A V, Chen M-H, Dehghan A, Aspelund T, Lin J-P, van Duijn CM, 
Harris TB, Cupples LA, Uitterlinden AG, Launer L, Hofman A, Rivadeneira F, Stricker B, Yang Q, 
O’Donnell CJ, Gudnason V, Witteman JC: Genome-wide association meta-analysis for total serum 
bilirubin levels. Hum Mol Genet 2009, 18:2700–10. 
41. Bielinski SJ, Chai HS, Pathak J, Talwalkar JA, Limburg PJ, Gullerud RE, Sicotte H, Klee EW, Ross 
JL, Kocher J-PA, Kullo IJ, Heit JA, Petersen GM, de Andrade M, Chute CG: Mayo Genome Consortia: 
a genotype-phenotype resource for genome-wide association studies with an application to the 
analysis of circulating bilirubin levels. Mayo Clin Proc 2011, 86:606–14. 
42. Dai X, Wu C, He Y, Gui L, Zhou L, Guo H, Yuan J, Yang B, Li J, Deng Q, Huang S, Guan L, Hu D, Zhu 
J, Min X, Lang M, Li D, Yang H, Hu FB, Lin D, Wu T, He M: A genome-wide association study for 
serum bilirubin levels and gene-environment interaction in a Chinese population. Genet 
Epidemiol 2013, 37:293–300. 
43. Lingenhel A, Kollerits B, Schwaiger JP, Hunt SC, Gress R, Hopkins PN, Schoenborn V, Heid IM, 
Kronenberg F: Serum bilirubin levels, UGT1A1 polymorphisms and risk for coronary artery 
disease. Exp Gerontol 2008, 43:1102–7. 
44. Bosma PJ, Chowdhury NR, Goldhoorn BG, Hofker MH, Oude Elferink RP, Jansen PL, Chowdhury 
JR: Sequence of exons and the flanking regions of human bilirubin-UDP-glucuronosyltransferase 
gene complex and identification of a genetic mutation in a patient with Crigler-Najjar syndrome, 
type I. Hepatology 1992, 15:941–7. 
45. Seppen J, Bosma PJ, Goldhoorn BG, Bakker CT, Chowdhury JR, Chowdhury NR, Jansen PL, Oude 
Elferink RP: Discrimination between Crigler-Najjar type I and II by expression of mutant bilirubin 
uridine diphosphate-glucuronosyltransferase. J Clin Invest 1994, 94:2385–91. 
46. Kadakol A, Ghosh SS, Sappal BS, Sharma G, Chowdhury JR, Chowdhury NR: Genetic lesions of 
bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar 
and Gilbert syndromes: correlation of genotype to phenotype. Hum Mutat 2000, 16:297–306. 
29 
47. Black M, Billing BH: Hepatic bilirubin udp-glucuronyl transferase activity in liver disease and 
gilbert’s syndrome. N Engl J Med 1969, 280:1266–71. 
48. Koiwai O, Nishizawa M, Hasada K, Aono S, Adachi Y, Mamiya N, Sato H: Gilbert’s syndrome is 
caused by a heterozygous missense mutation in the gene for bilirubin UDP-
glucuronosyltransferase. Hum Mol Genet 1995, 4:1183–6. 
49. Borlak J, Thum T, Landt O, Erb K, Hermann R: Molecular diagnosis of a familial nonhemolytic 
hyperbilirubinemia (Gilbert’s syndrome) in healthy subjects. Hepatology 2000, 32(4 Pt 1):792–5. 
50. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, Lindhout D, Tytgat GN, 
Jansen PL, Oude Elferink RP: The genetic basis of the reduced expression of bilirubin UDP-
glucuronosyltransferase 1 in Gilbert’s syndrome. N Engl J Med 1995, 333:1171–1175. 
51. Bulmer AC, Blanchfield JT, Toth I, Fassett RG, Coombes JS: Improved resistance to serum 
oxidation in Gilbert’s syndrome: A mechanism for cardiovascular protection. Atherosclerosis 
2008, 199:390–396. 
52. Inoguchi T, Sasaki S, Kobayashi K, Takayanagi R, Yamada T: Relationship between Gilbert 
syndrome and prevalence of vascular complications in patients with diabetes. JAMA 2007, 
298:1398–400. 
53. Dekker D, Dorresteijn MJ, Pijnenburg M, Heemskerk S, Rasing-Hoogveld A, Burger DM, 
Wagener FADTG, Smits P: The bilirubin-increasing drug atazanavir improves endothelial function 
in patients with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2011, 31:458–63. 
54. Beutler E, Gelbart T, Demina A: Racial variability in the UDP-glucuronosyltransferase 1 
(UGT1A1) promoter: A balanced polymorphism for regulation of bilirubin metabolism? Proc Natl 
Acad Sci 1998, 95:8170–8174. 
55. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, Belmont JW, Boudreau A, 
Hardenbol P, Leal SM, Pasternak S, Wheeler DA, Willis TD, Yu F, Yang H, Zeng C, Gao Y, Hu H, Hu 
W, Li C, Lin W, Liu S, Pan H, Tang X, Wang J, Wang W, Yu J, Zhang B, Zhang Q, Zhao H, et al.: A 
second generation human haplotype map of over 3.1 million SNPs. Nature 2007, 449:851–61. 
56. Oussalah A, Bosco P, Anello G, Spada R, Guéant-Rodriguez R-M, Chery C, Rouyer P, Josse T, 
Romano A, Elia M, Bronowicki J-P, Guéant J-L: Exome-Wide Association Study Identifies New 
Low-Frequency and Rare UGT1A1 Coding Variants and UGT1A6 Coding Variants Influencing 
Serum Bilirubin in Elderly Subjects: A Strobe Compliant Article. Medicine (Baltimore) 2015, 
94:e925. 
57. Bellis C, Cox HC, Ovcaric M, Begley KN, Lea RA, Quinlan S, Burgner D, Heath SC, Blangero J, 
Griffiths LR: Linkage disequilibrium analysis in the genetically isolated Norfolk Island population. 
Heredity (Edinb) 2008, 100:366–373. 
58. Aulchenko YS, Ripke S, Isaacs A, Van Duijn CM: GenABEL: an R library for genorne-wide 
30 
association analysis. Bioinformatics 2007, 23:1294–1296. 
59. Scharpf RB, Irizarry RA, Ritchie ME, Carvalho B, Ruczinski I: Using the R Package crlmm for 
Genotyping and Copy Number Estimation. J Stat Softw 2011, 40:1–32. 
60. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, Maller J, Sklar P, de 
Bakker PIW, Daly MJ, Sham PC: PLINK: A Tool Set for Whole-Genome Association and Population-
Based Linkage Analyses. Am J Hum Genet 2007, 81:559–575. 
61. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen WM: Robust relationship 
inference in genome-wide association studies. Bioinformatics 2010, 26:2867–2873. 
62. O’Connell J, Gurdasani D, Delaneau O, Pirastu N, Ulivi S, Cocca M, Traglia M, Huang J, Huffman 
JE, Rudan I, McQuillan R, Fraser RM, Campbell H, Polasek O, Asiki G, Ekoru K, Hayward C, Wright 
AF, Vitart V, Navarro P, Zagury J-F, Wilson JF, Toniolo D, Gasparini P, Soranzo N, Sandhu MS, 
Marchini J: A general approach for haplotype phasing across the full spectrum of relatedness. 
PLoS Genet 2014, 10:e1004234. 
63. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype 
maps. Bioinformatics 2005, 21:263–265. 
64. R-Development-Core-Team: R: A language and environment for statistical computing. 2015.  
 
  
31 
Figure Legends 
 
Fig 1: GWAS Manhattan plots for; A) Total Serum Bilirubin, and B) Direct Serum Bilirubin. Meff 
adjusted correction threshold of 1.84x10-7 is indicated by the horizontal dashed line. 
 
Fig 2: Magnified view displaying genomic structure of the UDP-glucuronosyltransferase gene family 
located on 2q37.1. All SNPs within this region that were tiled on the Illumina Human 610quad 
BeadChip are displayed. Meff adjusted correction threshold of 1.84x10-7 is indicated by the horizontal 
dashed line. Known gene isoforms are indicated by dashed vertical lines and labelled at the top of 
the plot. The bilirubin metabolising gene, UGT1A1, is shown highlighted in green. 
 
Fig 3: Linkage Disequilibrium plots for 29 SNPs contained within UDP-glucuronosyltransferase gene 
family. The 2 LD blocks are outlined in black; Block 1 spans SNPs 1-9, Block 2 spans SNPs 10-28. All 
SNP rs numbers are listed, with their chromosomal positioning relative to each other indicated at 
the top of the figure. 
 
Fig 4: Haplotype structure across the two identified LD blocks in the Norfolk Island cohort UDP-
glucuronosyltransferase gene family. Displayed haplotypes reside at >1% frequency in the 
genotyped samples. Connecting lines represent haplotype combinations: thick lines represent 
haplotype combinations that reside at >10%, thin lines >1% of samples.  
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Tables 
 
Table 1: Significantly heritable metabolic traits in the Norfolk Island population. 
 
Trait h2 P value 
Total protein 0.563 2.26E-04 
Globin 0.525 3.36E-04 
Total bilirubin 0.502 4.45E-05 
LDL-C 0.454 7.51E-05 
Cholesterol 0.426 8.41E-05 
Chlorine 0.426 8.41E-05 
Alkaline phosphatase 0.425 6.10E-04 
Urea 0.424 7.87E-04 
GGT 0.369 3.02E-03 
Albumin 0.358 9.01E-03 
Uric Acid 0.350 2.17E-03 
HDL-C 0.348 1.58E-02 
Direct Bilirubin 0.327 3.30E-02 
Creatinine 0.257 2.43E-02 
AST 0.251 3.81E-02 
Cholesterol/HDL-C ratio 0.225 2.42E-02 
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Table 2: Top Meff corrected SNPs associated with Total Serum Bilirubin. 
 
SNP CHR Position A1 A2 effB se_effB chi2.1df P value 
rs6744284 2 234625297 C T 3.278 0.395 68.90 1.87E-16 
rs3771341 2 234673239 C T 3.235 0.395 67.17 4.43E-16 
rs17863787 2 234611094 T G 3.044 0.379 64.48 1.70E-15 
rs6742078 2 234672639 G T 3.025 0.379 63.60 2.64E-15 
rs887829 2 234668570 G A 3.011 0.379 63.01 3.55E-15 
rs4148324 2 234672722 T G 3.011 0.379 63.01 3.55E-15 
rs4148325 2 234673309 C T 3.011 0.379 63.01 3.55E-15 
rs1105880 2 234601965 T C 2.829 0.368 59.13 2.46E-14 
rs1105879 2 234602202 T G 2.829 0.368 59.13 2.46E-14 
rs6725478 2 234615400 C T 2.711 0.378 51.40 1.18E-12 
rs2741045 2 234580140 C T 2.907 0.406 51.17 1.32E-12 
rs10168416 2 234597087 C G 2.827 0.400 49.85 2.55E-12 
rs2070959 2 234602191 A G 2.827 0.400 49.85 2.55E-12 
rs2741012 2 234508963 C T 2.887 0.415 48.43 5.20E-12 
rs2741027 2 234518011 G A 2.887 0.415 48.43 5.20E-12 
rs7608175 2 234599089 C G 2.536 0.364 48.41 5.27E-12 
rs10168155 2 234596836 C T 2.530 0.364 48.21 5.82E-12 
rs10171367 2 234597667 C G 2.530 0.364 48.21 5.82E-12 
rs2361502 2 234698790 T C 2.590 0.380 46.37 1.46E-11 
rs2925260 15 25869972 T C 18.764 2.825 44.11 4.56E-11 
rs2930593 15 25877815 C A 18.764 2.825 44.11 4.56E-11 
rs12654591 5 38271582 C A 13.063 2.075 39.63 4.34E-10 
rs2741023 2 234516714 G A 2.446 0.399 37.67 1.17E-09 
rs10179094 2 234597825 T A 2.347 0.386 37.06 1.58E-09 
rs7586110 2 234590527 T G 2.344 0.385 37.05 1.59E-09 
rs2221198 2 234658623 C T 2.251 0.374 36.33 2.29E-09 
rs4124874 2 234665659 A C 2.194 0.365 36.05 2.63E-09 
rs3755319 2 234667582 T G 2.194 0.365 36.05 2.63E-09 
rs4148326 2 234673462 T C 2.194 0.365 36.05 2.63E-09 
rs1876506 3 42547127 A G 13.734 2.308 35.43 3.61E-09 
rs4294999 2 234635467 A G 2.155 0.364 35.11 4.23E-09 
rs2008595 2 234637192 G A 2.155 0.364 35.11 4.23E-09 
rs4663963 2 234650193 T G 2.155 0.364 35.11 4.23E-09 
rs16892701 8 120525983 G A 11.336 2.077 29.79 6.25E-08 
rs16892482 8 120386382 A G 11.326 2.077 29.74 6.41E-08 
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Table 3: Haploview marker associations showing frequencies of the recessive alleles 
 
SNP 
Associated 
Allele 
High Bili 
Allele Freq 
Normal Bili 
Allele Freq 
OR (95% CI) Chi square P value 
rs2741012 T 0.415 0.188 0.33 (0.22 – 0.49) 31.93 1.60E-08 
rs2741023 A 0.431 0.239 0.41 (0.28 – 0.61) 20.06 7.52E-06 
rs2741027 A 0.415 0.188 0.33 (0.22 – 0.49) 31.93 1.60E-08 
rs7586110 G 0.500 0.251 0.33 (0.23 – 0.49) 32.33 1.30E-08 
rs10168155 T 0.654 0.326 0.26 (0.17 – 0.38) 48.96 2.62E-12 
rs10168416 G 0.492 0.194 0.25 (0.17 – 0.37) 51.93 5.75E-13 
rs4485562 G 0.800 0.626 0.42 (0.26 – 0.66) 14.44 1.00E-04 
rs10171367 G 0.654 0.326 0.26 (0.17 – 0.38) 48.96 2.62E-12 
rs10179094 A 0.500 0.249 0.33 (0.22 – 0.49) 32.83 1.01E-08 
rs7608175 G 0.654 0.326 0.26 (0.17 – 0.38) 49.11 2.42E-12 
rs1105880 C 0.646 0.271 0.20 (0.14 – 0.30) 68.04 1.60E-16 
rs2070959 G 0.492 0.194 0.25 (0.17 – 0.37) 51.93 5.75E-13 
rs1105879 G 0.646 0.271 0.20 (0.14 – 0.30) 68.04 1.60E-16 
rs17863787 G 0.623 0.249 0.20 (0.13 – 0.30) 70.15 5.51E-17 
rs6725478 T 0.631 0.300 0.25 (0.17 – 0.37) 51.58 6.88E-13 
rs6744284 T 0.577 0.222 0.21 (0.14 – 0.31) 66.86 2.91E-16 
rs4294999 G 0.715 0.429 0.30 (0.21 – 0.45) 35.46 2.61E-09 
rs2008595 A 0.715 0.429 0.30 (0.21 – 0.45) 35.46 2.61E-09 
rs4663963 G 0.715 0.429 0.30 (0.21 – 0.45) 35.46 2.61E-09 
rs2221198 T 0.672 0.402 0.33 (0.22 – 0.49) 31.32 2.18E-08 
rs4124874 C 0.715 0.427 0.30 (0.21 – 0.45) 35.86 2.12E-09 
rs3755319 G 0.715 0.427 0.30 (0.21 – 0.45) 35.86 2.12E-09 
rs887829 A 0.623 0.254 0.20 (0.14 – 0.30) 67.92 1.70E-16 
rs6742078 T 0.623 0.253 0.20 (0.14 – 0.30) 68.23 1.46E-16 
rs4148324 G 0.623 0.254 0.20 (0.14 – 0.30) 67.92 1.70E-16 
rs3771341 T 0.577 0.227 0.22 (0.15 – 0.32) 64.55 9.40E-16 
rs4148325 T 0.623 0.254 0.20 (0.14 – 0.30) 67.92 1.70E-16 
rs4148326 C 0.715 0.427 0.30 (0.21 – 0.45) 35.86 2.12E-09 
rs2361502 C 0.546 0.268 0.30 (0.21 – 0.45) 38.61 5.16E-10 
 Note: odds ratios are not adjusted for age and sex  
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Table 4: Haploview 'Tagger' analysis of the 29 GWAS associated chr2q37.1 SNPs identified 9 SNPs as 
tagging the allelic variation across the region. 
 
SNP Tested Alleles Captured 
rs4148325 
rs3771341,rs887829,rs1105879,rs4148325,rs6742078,rs17863787, rs1105880,rs6744284, 
rs4148324 
rs2008595 rs4294999,rs4148326,rs4663963,rs2221198,rs3755319,rs4124874,rs2008595 
rs6725478 rs6725478,rs10168155,rs10171367,rs7608175 
rs7586110 rs10179094,rs7586110 
rs10168416 rs10168416,rs2070959 
rs2741027 rs2741027,rs2741012 
rs2741023 rs2741023 
rs2361502 rs2361502 
rs4485562 rs4485562 
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Table 5: Metabolic trait correlation with serum bilirubin group 
 
Trait t P High Bili Mean Normal Bili Mean 
albumin 0.90 3.70E-01 41.75 41.43 
Body Mass Index* -1.91 3.00E-02 25.06 26.27 
body fat* -3.43 5.30E-04 26.63 30.67 
cholesterol/HDL-C ratio* -1.82 4.00E-02 3.94 4.29 
cholesterol* -2.71 4.00E-03 5.30 5.67 
creatinine 0.15 8.80E-01 80.19 79.90 
cardiovascular disease risk 0.40 6.90E-01 7.20 6.69 
diastolic blood pressure 0.51 6.90E-01 77.69 76.68 
globin 1.91 6.10E-02 30.29 29.34 
HDL-C 0.62 5.30E-01 1.44 1.41 
hip circumference* -2.04 2.00E-02 99.42 101.92 
Inbreeding  -0.42 3.40E-01 0.01 0.01 
LDL-C* -1.66 5.00E-02 2.66 2.86 
mean arterial pressure 0.26 8.00E-01 95.01 94.44 
Polynesian Admixture -1.41 8.50E-02 0.21 0.25 
pulse pressure 0.02 9.80E-01 52.31 52.26 
systolic blood pressure 0.29 6.10E-01 130.00 128.95 
type-2 diabetes risk* -2.31 1.00E-02 9.19 11.22 
total protein* 2.28 3.00E-02 72.10 70.79 
triglycerides* -2.15 2.00E-02 1.58 2.00 
urea -0.44 6.60E-01 5.49 5.58 
uric acid 0.53 6.00E-01 0.35 0.34 
waist circumference -1.91 1.30E-01 85.04 87.62 
waist-hip ratio 0.34 6.30E-01 0.86 0.86 
weight 0.20 5.80E-01 75.79 75.31 
 * significant at P<0.05 
 
 
Table 6: Functional annotation of the chr2q37.1 SNPs significantly associated with total serum 
bilirubin levels. SNPs displayed reside in regions other than introns. 
 
RefSNP ID NCBI Gene ID Gene Symbol Function Class Residue Amino Acid Position 
rs1105879 54578 UGT1A6 coding-nonsynonymous S 183 
rs2070959 54578 UGT1A6 coding-nonsynonymous A 180 
rs1105880 54578 UGT1A6 coding-synonymous L 104 
rs2008595 54659 UGT1A3 5'UTR - - 
rs2741045 54600 UGT1A9 5'UTR - - 
rs3755319 54658 UGT1A1 5'UTR - - 
rs7586110 54577 UGT1A7 5'UTR - - 
rs7608175 54578 UGT1A6 5'UTR - - 
rs887829 54658 UGT1A1 5'UTR - - 
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Additional Files 
- Additional File 1 (filetype: pdf): 
Title: Summary statistics of phenotypic traits measured in the Norfolk Island population. 
Description of data: Table with an overview of the Norfolk Island phenotype data analysed, 16 traits 
in total. 
 
- Additional File 2 (filetype: pdf): 
Title: GWAS Manhattan plots for metabolic related traits. 
Description of data: GWAS Manhattan plots for all 16 traits. 
 
- Additional File 3 (filetype: pdf): 
Title: LD lots for 4 populations across 200kb of  chr2q37.1. 
Description of data: Haploview LD plots for 25 SNPs spanning a region of chr2q37.1 for four 
populations; NI (Norfolk Island), CEU (European); CHD (Chinese), and JPT (Japanese).  
 
- Additional File 4 (filetype: pdf): 
Title: Haploview allele frequency data for 25 chr2q37.1 SNPs across 4 populations. 
Description of data: Minor allele frequencies for 25 SNPs across five populations; Norfolk Island (NI), 
European (CEU), Chinese (CHD and CHB), and Japanese (JPT). 
 
- Additional File 5 (filetype: pdf): 
Title: Detailed Haploview allele frequency data for all 29 SNPs in the NI cohort.  
Description of data: Allele frequency data for all 29 SNPs across the chr2q37.1 region for the Norfolk 
Island samples. 
38 
 
- Additional File 6 (filetype: pdf): 
Title: Haploview haplotype associations with bilirubin levels. 
Description of data: Haplotypes identified by Haploview and their association statistics. 
 
